Research firm HVIVO has announced that it hopes to commence the final stage of its study on human metapneumovirus (HMPV) ...
VIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human ...
Hvivo anticipates that full-scale Hmpv human challenge trials (HCTs) could commence in the second half of 2025 ...
Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...
Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...
During the randomised, placebo-controlled, double-blind study, healthy volunteers recruited by hVIVO's FluCamp were administered S-337395 once daily for five days. Results showed an 88.94% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results